Talc settlements will help J&J rebound

Article Excerpt

Medical giant Johnson & Johnson is now in the process of spinning off its consumer products business. That will let it focus on its more risky, but potentially more profitable, prescription drugs and medical device businesses. The stock has dropped 2% since the company announced that plan in November 2021. The decline is partly due to lawsuits claiming Johnson & Johnson’s talc baby powder causes ovarian cancer. The company is now replacing the talc with corn starch. It’s also moving to settle those suits, which should set it up for a post-spinoff rebound. JOHNSON & JOHNSON $163 is your #1 Spinoff Buy for 2023. The company (New York symbol JNJ; Consumer sector; Shares outstanding: 2.6 billion; Market cap: $423.8 billion; Dividend yield: 2.9%; Takeover Target Rating: Medium; www.jnj.com) is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. The company now plans to spin off its Consumer Health business (called Kenvue Inc.) as a separate firm. Its shares will trade on New…